leisure time -WSS

leisure time

author：focus 2025-09-06 10:59:04 - browse：49934

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： HPV vaccine, cervical cancer study delivers historic results

focus

WSS

How the drug

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Hospital at home shows how to bring innovation to health care

The inclusion problem at the heart of rehabilitation research

Wegovy improves function in certain heart failure patients

PBMs are inflating the cost of generic drugs. They must be reined in

explore

leisure time

Wikipedia

Affirmative action in medical school literally saved lives

How the drug

Malaria cases in Florida and Texas: Here’s what you need to know

Cardiologists urge adding sexual orientation, gender identity to health records

Apple is now the first public company to be valued at $3 trillion

FDA endorses new sterilization method for medical devices

Heart attack and stroke risk calculators need revising

Study: Spinal cord stimulation helps patients with paralysis walk again

Hepatitis C has a cure — but many Americans still lack access to it

FDA advisory panel to debate high blood pressure devices

explore

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Dana Farber says 6 studies to be retracted and 31 corrected

Head of FDA's diagnostics center, who led through Covid, retires

High breast density mammograms need follow

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

DeSantis wants to import drugs. Biden’s FDA blasted his plan

leisure time

Wikipedia

focus

hotspot